First patient dosed in Phase IIb imaging for Brain Mets
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
28 APRIL 2025
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in
U.S. Phase 2b Imaging Study of Brain Metastasis
Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain
metastases from solid tumors of different origins
Underscores Radiopharm’s commitment to developing transformative oncology
radiopharmaceuticals
Sydney, Australia – 28 April 2025 – Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX,
“Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on
developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
announced the dosing of the first patient in its U.S. Phase 2b imaging study of 18F-RAD101 in
suspected recurrent brain metastasis.
The U.S. multicenter, open-label, single arm Phase 2b clinical trial1 is evaluating the diagnostic
performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid
tumors of different origins. The primary objective of the study is concordance between 18F-RAD101
positive lesions and those seen in conventional imaging (MRI with gadolinium) in participants with
suspected recurrent brain metastases.
RAD101 is a novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme
protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including
cerebral metastasis. Disruption of FASN activity allows for the accurate detection of cancer cells,
representing a strongly viable target for the imaging of brain metastasis. Positive data from the
Imperial College of London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases
showed significant tumor uptake that was consistent with and independent from the tumor of
origin.2
“We are proud to pioneer the first U.S. clinical trial of RAD101,” said Harshad R. Kulkarni, MD, Chief
Medical Advisor at BAMF Health and Principal Investigator of this Phase 2b study. “This marks an
important step toward improving diagnostic precision and enabling more evidence-based,
individualized treatment decisions for patients with brain metastases following stereotactic
radiosurgery.”
“This trial is an excellent illustration of BAMF Health’s clinical trials platform in action,” added BAMF
Health’s Director of Clinical Trials. “Our Radiopharmacy is producing the imaging agent on-site, our
clinic team is caring for the patient and providing the best image in the world, and our clinical trials
team expertly coordinates it all. BAMF’s facility and team were built to do trials just like this.”
“Current standard of care imaging is less sensitive in discriminating between tumor recurrence and
radiation necrosis in patients with brain metastasis who have received anticancer treatments,
including radiation,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics
1 https://www.clinicaltrials.gov/study/NCT06777433
2 S. Islam et. Al., EJNMMI; 07 February 2025. https://doi.org/10.1007/s00259-025-07118-0
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
28 APRIL 2025
Ltd. “18F-RAD101 has the strong potential to improve diagnostic accuracy of brain metastases, and
holds promise for discriminating between treatment effect and true progression in the more than
300,000 patients diagnosed with brain metastasis each year in the U.S. alone. We look forward to
advancing this clinical trial and to reporting topline data in the second half of 2025.”
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The
company has a pipeline of distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes
one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and
brain. Learn more at radiopharmtheranostics.com.
About BAMF Health
BAMF Health is the world’s first vertically integrated platform for intelligence-based precision
medicine. Headquartered in Grand Rapids, Michigan, BAMF Health employs the most advanced
theranostic imaging technology to detect and treat cancer and other diseases and conduct advanced
clinical trials. Our overriding mission is to empower patients to become people again. With a team of
data scientists, researchers, software engineers, and clinicians —all working in lockstep—we’re
making good on it. To learn more about BAMF Health, visit www.bamfhealth.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
Radiopharm Theranostics
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Andrew Dymon
Precision AQ (formerly Stern IR)
andrew.dymon@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
28 APRIL 2025
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Share your feedback
Discover